Cellectis (NASDAQ:CLLS) Receives Market Outperform Rating from Citizens Jmp

Citizens Jmp reaffirmed their market outperform rating on shares of Cellectis (NASDAQ:CLLS) in a research report released on Tuesday,Benzinga reports. Citizens Jmp currently has a $8.00 price objective on the biotechnology company’s stock.

Other analysts also recently issued research reports about the stock. Jefferies Financial Group initiated coverage on shares of Cellectis in a report on Tuesday, February 17th. They set a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research note on Wednesday, January 21st. Finally, Clear Str upgraded shares of Cellectis to a “strong-buy” rating in a research note on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Cellectis currently has a consensus rating of “Moderate Buy” and an average price target of $6.75.

Cellectis Stock Performance

NASDAQ CLLS opened at $4.16 on Tuesday. Cellectis has a 52-week low of $1.33 and a 52-week high of $5.48. The company has a 50-day simple moving average of $3.62 and a 200 day simple moving average of $3.98. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.62 and a current ratio of 1.62. The company has a market capitalization of $417.41 million, a PE ratio of -6.21 and a beta of 2.91.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Thursday, March 19th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Cellectis had a negative return on equity of 69.38% and a negative net margin of 84.92%.The company had revenue of $15.50 million for the quarter, compared to analysts’ expectations of $10.74 million. On average, research analysts predict that Cellectis will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Cellectis

Several hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC bought a new stake in Cellectis during the fourth quarter valued at approximately $34,000. Acadian Asset Management LLC lifted its position in Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 26,461 shares during the last quarter. Delaney Dennis R bought a new stake in Cellectis during the third quarter valued at approximately $68,000. Virtu Financial LLC bought a new stake in Cellectis during the third quarter valued at approximately $72,000. Finally, Millennium Management LLC lifted its position in Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares during the last quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.